ASC37 is Ascletis’ investigational triple-agonist peptide, with a long-acting depot development program and company-reported animal and laboratory findings, but no clinical results found as of November 2, 2026.
ASC37 remains investigational, with no regulatory approval reported in the reviewed primary sources. The reviewed findings concern animal and laboratory studies, not demonstrated clinical outcomes.
What is the ASC37 triple agonist?
Ascletis describes ASC37 as a peptide activating GLP-1, GIP and glucagon receptors. Its July announcement describes a chain containing 41 amino acids. “Triple agonist” means activity at three receptor targets, not three proven clinical advantages. Molecular activity, animal observations and clinical findings answer different questions.
ASC37, ASC37i and ASC37o: read the suffix
Earlier Ascletis releases used ASC37 for both oral and depot formulation programs. Its current pipeline language separates ASC37i, designed for once-monthly to once-quarterly subcutaneous administration, from ASC37o, designed for once-weekly oral administration. These are company development objectives, not established clinical schedules. The October oral-pipeline announcement is particularly useful for decoding the names.
That matters when an “ASC37 Ascletis” search mixes older headlines with newer program labels. The monthly design discussed below concerns the depot program. It should not be pasted onto the oral program, and neither formulation inherits clinical findings from another Ascletis candidate. The suffix matters.
What has actually been shown?
| Claim | Source | Evidence level |
|---|---|---|
| Long-acting depot selected for development; observed half-life about 17 days in monkeys; formulation volume 1 mL or less | Ascletis, January 20 and July 27, 2026 | Company-reported, not peer reviewed; animal pharmacokinetics and formulation design |
| Body-weight reductions in diet-induced obese mice during an 11-day experiment; 41-amino-acid design | Ascletis, July 27, 2026 | Company-reported, not peer reviewed; mouse and molecular-design findings |
| ASC37 poster announced for November 14, 2026 | Ascletis, November 2, 2026 | Company-reported, not peer reviewed; conference announcement, not new clinical findings |
The reported monkey half-life is an animal observation and may not translate to people. In its January announcement, Ascletis compared approximately 17 days for an ASC37 depot formulation with approximately 2.5 days for retatrutide in a standard liquid formulation. Because the formulations differed, that comparison cannot isolate the contribution of the molecules themselves. The January announcement describes its observed measurement in relation to the time to half the peak concentration. That wording matters: a depot’s slow release can shape the concentration curve. A single half-life number is not a complete account of what the formulation does.
Why a monthly design is hard
A depot is a formulation designed to release material slowly. Think reservoir, not stopwatch. The research question is whether release remains sufficiently controlled across the intended interval. The phrase “once-monthly GLP-1” captures the ambition, but public ASC37 animal data do not demonstrate a monthly clinical schedule. Long-term safety is also unknown.
How to read the next announcement
A sponsor announcement tells us what the company chose to disclose. A full paper allows closer inspection of methods, analysis and limitations. Neither an attractive headline nor a conference slot substitutes for that detail. The November poster title includes a comparison with retatrutide in monkeys. It supplies no basis for ranking clinical safety or effectiveness.
Ascletis scheduled both the ASC37 and ASC48 posters for November 14, 2026, from 7:30 to 8:30 p.m. Eastern at Gaylord National. ASC48 is a separate oral small molecule GIP receptor agonist. Watch for the actual posters, an IND announcement and a first clinical registration. Update the evidence label only when the underlying evidence changes.
Related research reading
Place this program in context with Xcel’s obesity pipeline overview, UBT251 Phase 2 analysis, UBT251 and retatrutide receptor background, retatrutide Phase 3 reporting and Eloralintide research guide. These provide background, not evidence that ASC37 matches another program. For Ascletis’ oral small molecule program, see our ASC30 research update.
ASC37 FAQ
What is ASC37?
ASC37 is Ascletis’ investigational peptide targeting GLP-1, GIP and glucagon receptors. The reviewed public findings concern animal and laboratory studies.
Are ASC37, ASC37i and ASC37o interchangeable names?
Earlier announcements used ASC37 for different formulation programs. Current Ascletis materials distinguish the long-acting depot program, ASC37i, from the oral program, ASC37o. Evidence must stay attached to the formulation studied.
Have ASC37 findings been reported in people?
No ASC37 clinical results were found in the reviewed primary sources as of November 2, 2026. Animal observations do not establish clinical effectiveness or safety.
Does a monkey half-life establish a monthly clinical schedule?
No. The company’s animal pharmacokinetic observations inform a development goal. They do not establish a schedule or long-term safety in people.
What happens next in ASC37 research?
Ascletis announced an ObesityWeek poster for November 14, 2026. Additional milestones to watch include an IND announcement and a first clinical trial registration.
All products supplied by Xcel Research LLC are chemical reference materials intended solely for in vitro laboratory research. They are not drugs, foods, dietary supplements, cosmetics, or medical devices, and have not been approved by the FDA for the diagnosis, treatment, cure, or prevention of any disease or condition. These materials are not for human or veterinary use and may not be administered to humans or animals under any circumstances.